close

ISTA Pharmaceuticals, Inc., an ophthalmic pharmaceutical company, discovers, develops, and markets therapies for inflammation, ocular pain, glaucoma, allergy, and dry eye in the United States. The company offers Xibrom for the treatment of inflammation and pain following cataract surgery; Istalol for the treatment of glaucoma; and Vitrase for use as a spreading agent. Its developing products include Bepotastine ophthalmic solution for allergic conjunctivitis; T-Pred, a Phase III clinical trial product candidate for the treatment of steroid-responsive inflammatory ocular conditions; Ecabet Sodium, a Phase IIb clinical trial product, for the treatment of dry eye syndrome; and Bepotastine nasal for the treatment of allergic rhinitis. The company's products developing products also include a steroid product candidate to treat ocular inflammation; iganidipine to enhance ocular nerve blood flow; and a formulation of latanoprost for the treatment of glaucoma. It sells its products primarily to drug wholesalers, retailers, and distributors, including chain drug stores, hospitals, clinics, government agencies, and managed healthcare providers. ISTA Pharmaceuticals was formerly known as Advanced Corneal Systems, Inc. and changed its name to ISTA Pharmaceuticals, Inc. in March 2000. The company was founded in 1992 and is headquartered in Irvine, California.

(login to add this stock to your watchlist or favorites)

Key Statistics

Closing Price	8.65
Volume	445512
Volume Avg	525333
52 Week High	11.39
52 Week Low	2.88
PE	N/A
PE (group average)	39
EPS Year	-1.47
EPS change Q/Q	-64.29%
EPS change Q/Q Yr ago	-1150%
EPS change Q/Q next Q est	1000%
EPS change Y/Y	-987.5%
REV change Q/Q	21.67%
REV change Q/Q Yr ago	48.98%
EPS next Q est	0.07
EPS next Y est	0.65
Divident Annual	0.00
Dividend Yield	0%